Earlier studies have demonstrated that single-target CAR-T therapies, such as those targeting the CD19 antigen, often confront resistance due to CD19 antigen loss, while CD22 remains stably expressed in relapsed B-ALL patients (SI Fig. S1) [15]. The gene discussed is CD19; the disease is precursor B-cell acute lymphoblastic leukemia.